The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

I farmaci biologici nelle malattie infiammatorie croniche intestinali / L. Spina, L. Pastorelli, G. De Nucci, F. Cavallaro, G.E. Tontini, N. Munizio, M. Vecchi. - In: GIORNALE ITALIANO DI ENDOSCOPIA DIGESTIVA. - ISSN 0394-0225. - 36:3(2013), pp. 179-183.

I farmaci biologici nelle malattie infiammatorie croniche intestinali

L. Pastorelli;G.E. Tontini;M. Vecchi
2013

Abstract

The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
Adalimumab; Crohn's disease; Infliximab; Ulcerative colitis
Settore MED/12 - Gastroenterologia
2013
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/686891
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact